Cardiovascular-Renal-Metabolic is a top priority. Current efforts include design and screening of anti-diabetes and anti-obesity drug candidates; as well as anti-hypertensives. Small molecule drugs and peptide ligand candidates are in active design and screening.

Oncology is a key focus area of Deep EigenMatics. We are actively designing and screening anti-cancer agents using multiple priors and our proprietary AI/ML platform for drug safety and efficacy profile optimization.

Our unique and proprietary AI/ML platform enables rapid generation of a vast diversity of anti-bodies against specified antigens. EigenMatics™ AI platform enables the specific design of monoclonal synthetic biologic drug candidates for pre-clinical and clinical testing.

Neurology is an area of conspicuously unmet need. Our unique and proprietary AI/ML platform enables rapid generation of drug candidates for conditions such as Alzheimer's Disease, Parkinson's Disease, stroke, multiple sclerosis, and Amyotrophic Lateral Sclerosis (ALS).

Ophthalmology has several areas of unmet need including in glaucoma, macular degeneration, and diabetic retinopathy. Our unique and proprietary AI/ML platform, EigenMatics™, enables us rapidly design a vast library of ophthalmic drug candidates for pre-clinical and clinical testing.